The present invention concerns a package comprising an acidic citrate containing concentrate, an acidic citrate containing concentrate (or acidic citrate containing solution), and a system wherein the acidic citrate containing concentrate is included for providing a dialysis treatment. The acidic citrate containing concentrate contains citric acid and citrate in a molar ratio of 75:25 to 85:15, and has a pH of between 2 and 3.

Described are peritoneal dialysis systems and methods that involve the use of crossflow filtration of a used dialysate withdrawn from the peritoneal space of a patient. The filtration forms a retentate containing amounts of an osmotic agent and a permeate containing amounts of water and nitrogen-containing waste products of the patient. The retentate, or a fraction thereof, can be returned to the peritoneal space of the patient to return osmotic agent to the patient. The permeate, or a fraction thereof, can be discarded to discard nitrogen-containing waste products of the patient.

Disclosed herein are systems and methods for automated insulin delivery that provide for adaptive closed loop control that can modify the stored basal profile used by the closed loop algorithm to better reflect the user's actual needs. Actual delivery rates calculated by the closed loop algorithm can be compared to the user's stored profile. If the differences between the actual delivery rates and the stored profile are statistically significant, the stored profile can be modified.

In an infusion pump system that includes a pump that may have a user interface for pump programming, one or more smartphones or other remote control devices that interface with the infusion pump, and/or an automated insulin delivery algorithm, there is a potential conflict between commands such as boluses being programmed on multiple devices and/or calculated by the AID algorithm at the same time. In order to avoid low glucose levels that could result from delivering multiple boluses from these various sources when only one bolus is needed, systems and methods disclosed herein provide a bolus permissions and prioritization scheme that prioritizes boluses programmed with the infusion pump and one or more remote control devices and calculated by a closed loop delivery algorithm.

A system for adjusting blood glucose level including an insulin delivery device configured to release insulin into the body of a person, and an EEG monitor having an EEG sensing part including EEG electrodes. The EEG monitor can be arranged in the ear region of the person with the EEG sensing part arranged subcutaneously at the scalp or arranged in the ear canal. The EEG monitor includes an EEG signal processor arranged at the ear and adapted for identifying onset of hypoglycemia. The system further includes a wireless link between the EEG monitor and the insulin delivery device. The EEG monitor is configured to submit a warning signal to the insulin delivery device if an upcoming onset of hypoglycemia is identified. The warning message will cause the insulin delivery device to restrict insulin delivery for a predetermined time, and a warning is provided to the person or to a caregiver.

Techniques for glucose level management are disclosed. In some examples, the techniques may involve obtaining an estimated protein value for a meal and determining an equivalent carbohydrate value for the meal based on the estimated protein value. In some examples, the techniques may involve obtaining an estimated fat value for a meal and determining, based on the estimated fat value, a glucose absorption rate resulting from consumption of the meal. In some examples, the equivalent carbohydrate value and/or the glucose absorption rate may be used to determine an amount of insulin to deliver to a patient to counteract a glucose level increase caused by consumption of the meal. The techniques may further involve generating an output indicative of the amount of insulin to deliver to the patient to counteract the glucose level increase caused by consumption of the meal.

The invention relates to a device for treating an individual suffering from cardiac or circulatory arrest or from a stroke, comprising a blood withdrawal device (BE) that is applied to the individual (P), an analysis unit (BA) which is directly or indirectly connected to the blood withdrawal device for detecting a blood analysis result (BAE) providing at least one characteristic of the blood, directly or indirectly connected to a blood return device (BR) that is applied to the individual (P) and is designed to deliver a substance to the individual via the return device (BR).

An apparatus used in analyzing spent dialysate includes: at least one surface configured to accommodate a dialysate drain bag or drain line in a predetermined position; a light source positioned to emit light through the dialysate drain bag or drain line; and a light sensor positioned to sense light emitted by the light source through the dialysate drain bag or drain line.

Disclosed is a method of treating microbial infections and their associated complications in humans. The method includes administering to a patient, a composition of dextrose and ethanol. The composition can be administered in the form of an infusion. For patients suffering from respiratory complications, the disclosed method also provides for enhancing oxygen uptake by lungs and reducing oxygen resistance through the administration of air having helium gas and excited oxygen atoms.

Disclosed are processes and techniques for a correction factor determination process for determining a correction factor for delivering a drug to a patient via a drug delivery device. For example, for an insulin delivery device, the disclosed techniques enable adjustment of the patient’s correction factor in real time based on the deviation of the patient’s glucose concentrations against clinically recommended targets. For example, a method for determining a correction factor may include determining an insulin action (I.sub.action) for a patient over a duration, the insulin action representing a total insulin metabolized, determining glucose information for the patient over the duration, the glucose information representing glucose activity, and determining an estimated correction factor (CF.sub.est) based on (glucose information) / (insulin action) for the duration. Other embodiments are described.